OCREVUS ZUNOVO J Code: J2351

Drug & Product Overview

HCPCS Descriptor Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq

HCPCS Added Date April 1, 2025

Manufacturer Genentech

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About OCREVUS ZUNOVO

Ocrevus Zunovo is a medication aligned to the HCPCS J Code: J2351 for billing, pricing, and reimbursement purposes in the United States. Classified under Immunology, it is administered via the subcutaneous route and manufactured by Genentech.

According to CMS Drug Use Information: This medication is used to treat certain forms of multiple sclerosis-MS (relapsing or primary progressive forms). It contains 2 ingredients: ocrelizumab and hyaluronidase. This medication is not a cure for MS, but it is thought to help slow down nerve damage, reduce the number of relapses, and delay disability. Ocrelizumab belongs to a class of drugs known as monoclonal antibodies. Hyaluronidase is used to help the body absorb ocrelizumab, which helps it work better.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
50242-0554-01	Ocrevus Zunovo	Genentech, Inc.	920	920 MG / 23 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

OCREVUS ZUNOVO Pricing & Reimbursement

J2351 Private Payer Reimbursement

$47.08 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

OCREVUS ZUNOVO CPT Administration Codes

CPT Code	Description
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

OCREVUS ZUNOVO Medically Unlikely Edits (MUE)

The most billing units of J2351 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

920 units / day

= 920 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

OCREVUS ZUNOVO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Primary progressive multiple sclerosis Relapsing forms of multiple sclerosis

Drug Class

AntibodiesMonoclonal [CS]MonoclonalHumanized [CS]CD20-directed Antibody Interactions [MoA]CD20-directed Cytolytic Antibody [EPC]Endoglycosidase [EPC]Glycoside Hydrolases [CS]

Frequently Asked Questions

Is there a manufacturer-published OCREVUS ZUNOVO billing and coding guide?

Billing and coding information for OCREVUS ZUNOVO can be found through Genentech Inc. Visit Here →

What are the available OCREVUS ZUNOVO patient assistance programs?

OCREVUS ZUNOVO patient assistance information can be found through Genentech Inc. Visit Here →

Where can I find OCREVUS ZUNOVO prescribing information?

OCREVUS ZUNOVO prescribing information can be found at the link below. Visit Here →

Where can I find OCREVUS ZUNOVO side effect information?

Side effect information for OCREVUS ZUNOVO can be found at the following source.

Does billing OCREVUS ZUNOVO require JZ/JW wastage modifiers?

CMS does not include OCREVUS ZUNOVO (J2351) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J2351. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.